Latest news

New Anti-PD1 / Anti-PD-L1 Explicyte Shuttle

09 / 13 / 2016

After a full session in September, the next explicyte shuttle – anti-PD1 / anti-PDL1 syngeneic mouse models – is scheduled for the 25th of October.

The explicyte shuttle is a standardized study protocol in which you can include experimental groups in an already programmed study. Explicyte will cover the costs of the vehicle control group + the standard reference and sponsor will only cover its experimental groups.
 

In Vitro Immune Cell Killing Of Tumor Cells

07 / 12 / 2016

Cancer immunoediting is a dynamic process which consists in three phases including elimination, equilibrium and tumor immune escape. During the elimination step there is an engagement of effector cells such as natural killer or T cells which initiate tumor cell death – an event defective in case of tumor progression. Such key mechanism thus warrants investigation to optimize immune cell mediated killing of tumor cell. To this aim, we developed immune / tumor cells co-culture on a 96-well throughput platform to evaluate the capacity of candidate compounds to promote immune cell dependent tumor cell death alone and/or in combination with immune checkpoint inhibitors.
 

Take Part Of The Next Anti-PD1 / Anti-PD-L1 Explicyte Shuttle

06 / 29 / 2016

The comparison of the efficacy of a drug candidate with the gold standard anti-PD1 / anti-PD-L1 immunotherapy and/or evaluation of its ability to potentiate PD1/PD-L1 blockade mostly relies on immunocompetent mouse models in which the response to PD1/PD-L1 blockade has been already validated (see our recent news).

In the next explicyte shuttle, we offer our clients to include experimental groups in an already scheduled study. In this session, explicyte will cover the costs of vehicle and anti-PD1 and/or anti-PDL1 treated groups and sponsor will only cover its experimental groups (eg. drug candidates alone or in combination with anti-PD1 and/or anti-PDL1 mAbs).

The next explicyte shuttle is scheduled for the 19th of September!
 

PD1 / PDL1 Blockade In Mouse Tumor Syngeneic Models

06 / 02 / 2016

Combinatory approaches in immuno-oncology with immune checkpoint inhibitors including anti-PD1 / PDL1 or anti-CTLA4 therapeutic antibodies is an active field of investigation. In order to evaluate potential synergistic effect of novel chemotherapeutic agents, immunostimulatory compounds, etc., we characterized the clinical response to anti-PD1 and anti-PDL1 in immunocompetent animal models. Ancillary studies including FACS analysis, RT-qPCR can provide support to delineate mechanism of actions of a drug candidate and can also support the identification of novel predictive biomarkers.
 

Take Part Of The Next Anti-CTLA4 Explicyte Shuttle

05 / 19 / 2016

The comparison of the efficacy of a drug candidate with the gold standard anti-CTLA4 immunotherapy and/or evaluation of its ability to potentiate CTLA4 blockade mostly relies on immunocompetent mouse models in which the response to CTLA4 blockade has been already validated (see our recent case study).

In the next explicyte shuttle, we offer our clients to include experimental groups in an already scheduled study. In this session, explicyte will cover the costs of vehicle and anti-CTLA4 treated group and sponsor will only cover its experimental groups (eg. drug candidates alone or in combination with anti-CTLA4 mAb).

The next explicyte shuttle is scheduled for the 21th of June!
 

Anti-CTLA-4 Response In Mouse Tumor Syngeneic Models

04 / 27 / 2016

In order to improve the benefit of anti-CTLA4 immunotherapy the current challenges the pharma industry are facing are the:

  • Development and evaluation of novel test compounds able to synergize with anti-CTLA-4
  • Discovery of novel molecular mechanisms underlying the resistance to anti-CTLA4 blockade
  • Identification of biomarkers capable to predict response to anti-CTLA4 therapy

At a preclinical stage, these points can be addressed using immunocompetent animal models in which the response to reference immune checkpoint inhibitors is validated. This is why we characterized the clinical response to anti-CTLA4 immunotherapy in mouse syngeneic tumor models and selected the most sensitive to further investigate the cellular and molecular features of the immune response associated with clinical efficacy.
 

Preclinical Mouse Tumor Models Of Immune Checkpoint Inhibition

01 / 28 / 2016

To test novel combination therapies aiming at increasing responses rates to immune checkpoint inhibitors, Explicyte has optimized a range of syngeneic mouse tumor models treated with anti-CTLA-4 or anti-PD-1/PD-L1 monoclonal antibodies. Starting with basic measurements of in vivo efficacy, our in vivo services extends to comprehensive biomarker studies, to determine the in vivo mechanism of action of novel treatments.

 

Syngeneic Mouse Model Of Glioblastoma

01 / 22 / 2016

To assess the in vivo efficacy and mechanism of action of novel therapeutic strategies for brain cancer, Explicyte has validated a syngeneic mouse tumor model of glioma, which closely mimics human glioblastoma (GBM) in terms of tumor progression and immune response. A key advantage of this model, based on the GL261-Luc2 murine glioma cell line, relies on the possibility of quantifying tumor growth in live animals by bioluminescence imaging along the study.